Abstract | BACKGROUND: Despite the increasing number of antiretroviral compounds, the number of useful drug regimens is limited owing to the high frequency of cross-resistance. PATIENTS AND METHODS: We studied in vitro two- drug combinations using three protease inhibitors (PIs), tipranavir, amprenavir and lopinavir, on isolates (003 and 004) derived from patients with resistance to multiple PIs compared with the drug-susceptible isolate 14aPre in peripheral blood mononuclear cells. Drug interactions were determined by median dose-effect analysis, with the combination index calculated at several inhibitory concentrations (IC). RESULTS: CONCLUSIONS: Our in vitro experiments did not show any advantage in combining second generation PIs as a therapeutic strategy in naive or multi-treatment failure subjects, with the exception of tipranavir + amprenavir at IC(95) in infections by a wild-type isolate.
|
Authors | Elisabetta Bulgheroni, Paola Citterio, Francesco Croce, Mirko Lo Cicero, Ottavia Viganò, Francesca Soster, Ting-Chao Chou, Massimo Galli, Stefano Rusconi |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 53
Issue 3
Pg. 464-8
(Mar 2004)
ISSN: 0305-7453 [Print] England |
PMID | 14963061
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Carbamates
- Furans
- HIV Protease Inhibitors
- Pyridines
- Pyrimidinones
- Pyrones
- RNA, Viral
- Sulfonamides
- Lopinavir
- amprenavir
- tipranavir
|
Topics |
- Carbamates
- Drug Resistance, Viral
- Enzyme-Linked Immunosorbent Assay
- Furans
- Genotype
- HIV Infections
(virology)
- HIV Protease Inhibitors
(pharmacology)
- HIV-1
(drug effects)
- Humans
- Lopinavir
- Pyridines
(pharmacology)
- Pyrimidinones
(pharmacology)
- Pyrones
(pharmacology)
- RNA, Viral
(biosynthesis, genetics)
- Sulfonamides
(pharmacology)
|